Somatostatin analogs (e.g., octreotide, lanreotide) will continue to be main therapies for functioning neuroendocrine tumors over the next years. Pasireotide, a new panreceptor analog, might ...

It might also reduce the size of your cancer. Common somatostatin analogue drugs used are octreotide and ... So not everyone with a NET can have this treatment. Somatostatin analogues are not a ...

Lutathera is a type of radioactive drug that treats patients with GEP-NET. The drug binds to a receptor called somatostatin — found on some neuroendocrine tumor cells — in ... with long-lasting ...

Neuroendocrine tumors (NETs ... One way your doctor can check whether you have a NET is to take advantage of the fact that some tumors release hormones and proteins. They can do tests that ...

and locations of NET. A doctor can provide a clearer picture of a person’s outlook based on their individual circumstances. Neuroendocrine tumors (NETs) develop on nerves on hormone-producing ...

Most NET cells have receptors on their surface. These attract and take up (absorb) certain substances. These substances include octreotide ... Most people have several tests to diagnose a ...

SEATTLE, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that two ...

SEATTLE, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), announced today that the first patient was dosed at the ...

announced initial results from its ongoing Phase 1/2a clinical trial of [212 Pb]VMT-α-NET that are being presented at the 2024 North American Neuroendocrine Tumor Society (NANETS ...

Small cell lung cancer (SCLC) and other neuroendocrine tumors (NETs ... doctors refer to it as a lung NET. These tumors may not cause noticeable symptoms, which can delay diagnosis.

Somatostatin analogs (e.g., octreotide, lanreotide) will continue to be main therapies for functioning neuroendocrine tumors over the next years. Pasireotide, a new panreceptor analog, might ...